We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » China Fines GlaxoSmithKline $490 Million for Bribery
China Fines GlaxoSmithKline $490 Million for Bribery
British drugmaker GlaxoSmithKline must pay a fine of roughly $490 million and change its business practices in China after a Chinese court found the company guilty in a year-old bribery case.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor